Dissecting the heterogeneity of triple-negative breast cancer.

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes. This is observed despite its usual high sensitivity to chemotherapy. In the advanced setting, responses observed with chemotherapy lack durability. Early-stage clinical studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction. The molecular complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies. In this review, we discuss the biology of TNBC at the pathologic and the molecular levels. We also elaborate on the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC.

[1]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[3]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[4]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[5]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. J. van de Vijver,et al.  An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Pusztai,et al.  Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer , 2010 .

[8]  D. Birnbaum,et al.  Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.

[9]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[10]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[11]  M. Gilcrease Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009 .

[12]  Yudi Pawitan,et al.  Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients , 2006, Breast Cancer Research.

[13]  E. Perez,et al.  RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[15]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[16]  J. Baselga,et al.  Treatment of HER2-overexpressing breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[18]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[19]  Scott H. Kaufmann,et al.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[22]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[23]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  C. Perou,et al.  Mammary development meets cancer genomics , 2009, Nature Medicine.

[25]  J. Hoeijmakers Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[26]  I. Tannock Effects of food on bioavailability of lapatinib: useful data, wrong conclusion. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. McClenathan,et al.  Adenoid cystic breast cancer. , 2002, American journal of surgery.

[28]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[29]  A. Bednarek,et al.  Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer , 2006, Oncology.

[30]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[31]  R. Gelber,et al.  Abstract P5-13-01: Patterns of Breast Cancer Relapse According to Breast Cancer Subtypes in Lymph Node-Negative Breast Cancer — Results from International Breast Cancer Study Group Trials VIII and IX , 2010 .

[32]  M. Sanders,et al.  Abstract PD01-07: Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies , 2010 .

[33]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[34]  E. Scarpi,et al.  Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Makris,et al.  DNA repair signature is associated with anthracycline response in triple negative breast cancer patients , 2010, Breast Cancer Research and Treatment.

[36]  J. Doroshow,et al.  Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 , 2011 .

[37]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[38]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[39]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[40]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[43]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Perou,et al.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.

[45]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[46]  J. Lubiński,et al.  Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Silver,et al.  Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.

[48]  I. Andrulis,et al.  Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. , 2000, Carcinogenesis.

[49]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[50]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[51]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[52]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Luini,et al.  Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity , 2009, Breast Cancer Research and Treatment.

[54]  G. Lenoir,et al.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region , 1998, Oncogene.

[55]  L. Wang,et al.  Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial. , 2010 .

[56]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[57]  E. Winer,et al.  A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. , 2010 .

[58]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[59]  J. Benítez,et al.  Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.

[60]  J. Albeck,et al.  Uncovering a Tumor Suppressor for Triple-Negative Breast Cancers , 2011, Cell.

[61]  M. Stratton Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[62]  T. Naab,et al.  Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome , 2007, Annals of Surgical Oncology.

[63]  Yuan Qi,et al.  Multifactorial approach to predicting resistance to anthracyclines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Albanell,et al.  Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[66]  E. Perez,et al.  Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.

[67]  D. Miles,et al.  Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). , 2009 .

[68]  Puay Hoon Tan,et al.  Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.

[69]  R. DePinho,et al.  Cancer chromosomes in crisis , 2004, Nature Genetics.

[70]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[71]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[72]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[74]  K Miller,et al.  A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[77]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[78]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[79]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[80]  T. Nielsen,et al.  Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  S. Powell,et al.  BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II , 2007 .

[82]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[83]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[84]  J. Thigpen Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .

[85]  K. A. Gelmon Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[86]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[87]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[88]  G. Moreno-Bueno,et al.  Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype: An Immunohistochemical and Gene Amplification Study , 2007, The American journal of surgical pathology.

[89]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[92]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[94]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[95]  C. Perou,et al.  Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. , 2010 .

[96]  C. Perou,et al.  TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .

[97]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[98]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[99]  R. Coates,et al.  Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA , 2008, Breast Cancer Research and Treatment.

[100]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[103]  C. Desmedt,et al.  Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer. , 2010 .

[104]  B. Iacopetta,et al.  Reply to C. Badoual et al , 2009 .

[105]  L. Esserman,et al.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.

[106]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[107]  Charles M Perou,et al.  Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  T. Helleday,et al.  PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination , 2009, The EMBO journal.

[109]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[110]  T. Traina,et al.  Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.

[111]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[112]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  E. Perez,et al.  RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. , 2009 .

[114]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[115]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[116]  F. Moinfar Is ‘Basal-Like’ Carcinoma of the Breast a Distinct Clinicopathological Entity? A Critical Review with Cautionary Notes , 2007, Pathobiology.

[117]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  M. Fernö,et al.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers , 2007, Breast Cancer Research.

[119]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  C. Perou,et al.  The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.